Advertisement

Radiopharmaceuticals for Treatment of Metastatic Castration-Resistant Prostate Cancer
Posted: 10/21/2022 | By: Larry Rosenberg, PhD

Question 1 of 5

Radium-223 dichloride (Ra-223) is currently approved for the treatment of patients with castration-resistant prostate cancer (CRPC) and:

Choose 1

A
Bone or visceral metastases
B
Prostate-specific membrane antigen (PSMA)-positive disease
C
Symptomatic bone metastases and no known visceral metastatic disease
D
No bone metastases

CategoriesView All Quizzes

Tumor Type


Additional Topics



Conference Coverage